Search
In light of disappointing outcomes from CAR-T drug candidate trials, BioNTech intends to downscale its cell therapy production at its US facility. Meanwhile, United Laboratories has secured an advance payment of $180 million from Novo Nordisk. United Imaging Intelligence has successfully concluded a Series A funding round, raising RMB 1 billion. Recently, several new drugs have achieved significant milestones. Simcere Pharmaceutical's insomnia medication Dalirexin and Verium Pharma's WEYZ-1 cream have obtained clinical trial permits or marketing approval. Ideaya Biosciences' small molecule GLP-1 receptor agonist has advanced successfully through Phase 2b clinical trials. Furthermore, Dupilumab has been approved by the FDA for the treatment of bullous pemphigoid.
-
C114 Communication Network -
Communication Home
